Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

128.88 USD -1.24 (-0.95%)
Streaming Delayed Price Updated: 1:11 PM EST, Jan 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 370,268
Open 130.53
Bid (Size) 128.88 (1)
Ask (Size) 129.00 (2)
Prev. Close 130.12
Today's Range 128.00 - 131.99
52wk Range 125.08 - 212.00
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2021 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2021 on... 
From Business Wire News Releases
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development... 
From Business Wire News Releases

Performance

YTD
-25.89%
-25.89%
1 Month
-20.00%
-20.00%
3 Month
-32.58%
-32.58%
6 Month
-29.23%
-29.23%
1 Year
-24.20%
-24.20%

More News

Read More
Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting
From Business Wire News Releases
Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics Based on Proprietary U1 Adaptor Technology
From Business Wire News Releases
n-Lorem Foundation Partners with Alnylam to Expand Technology Access to RNAi Therapeutics for Patients with Nano-rare Diseases
From Business Wire News Releases
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2021 Global Net Product Revenues and Provides Additional Updates
From Business Wire News Releases
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
From Business Wire News Releases
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
Tags BZI/CROSS Benzinga Market News
From Benzinga
Soleo Health to Administer OXLUMO™ for the Treatment of Primary Hyperoxaluria Type 1
From Business Wire News Releases
Alnylam Announces Promotion of Dr. Akshay Vaishnaw to President
From Business Wire News Releases
Alnylam' Reveals Detailed 18-Month Data From Vutrisiran Trial In Inherited Disease
Tags Benzinga Briefs Health Care
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.